Eli Lilly & Company Oral Obesity Prescription Tracker

Research evidence excerpt

Eli Lilly & Company Oral Obesity Prescription Tracker

J P M O R G A N North America Equity Research

22 May 2026

Eli Lilly & Company Overweight

LLY, LLY US

Oral Obesity Prescription Tracker Price (21 May 26):$1,041.65

Pharmaceuticals — Major &

The impact of oral GLP1s on the obesity market has become a topic of debate for Specialty

LLY. Here, we distinctly see the launch of orals as category expanding (targeting Chris Schott, CFA AC

lower BMI / needlephobic / more cost-sensitive patients) and expect minimal (1-212) 622-5676

impact on uptake for Zepbound (which we view as still best in class on tolerability/ christopher.t.schott@jpmorgan.com

efficacy). Along these lines, we view a solid initial ramp of oral Wegovy as a Ethan Brown

positive for the class and as having a positive read-through to LLY’s launch of (1-212) 622-4928

ethan.brown@jpmchase.com

orforglipron.

Taylor Hanley

Early data continue to show strong uptake of oral Wegovy, with ~143k TRx per (1-212) 622-0790

taylor.hanley@jpmchase.com

IQVIA as of the 19th week of launch, which compares with ~137.3k TRx per

Hardik Parikh, CFA

IQVIA the prior week (and with earlier data points from Novo indicating that (1 212) 622-2875

IQVIA data are somewhat understated). And looking to Foundayo, IQVIA data hardik.k.parikh@jpmorgan.com

reflects 16,698 TRx for the 6th week of launch following 10,248 TRx last week Ekaterina V Knyazkova, CFA

(and with LLY noting >20k pts on drug to date on its 1Q call on 4/30). (1-212) 622-9576

ekaterina.v.knyazkova@jpmchase.com

Finally, looking to the injectable market, we have not seen any signs of the ramp J.P. Morgan Securities LLC

impacting uptake or the rate of new starts for Zepbound, which continues to

account for the majority of new adds in the category (largely led by strong vial /